French Sensorion SA has reported new efficacy endpoints data from SENS-401 in a Phase II study for the preservation of residual hearing loss.
ADVERTISEMENT
Log in here to read the desired article.
French Sensorion SA has reported new efficacy endpoints data from SENS-401 in a Phase II study for the preservation of residual hearing loss.

